
Web Release Date: March 21,
Comprehensive Proteomic Analysis of Human Cervical-Vaginal Fluid







and

Departments of Pediatrics and Obstetrics and Gynecology, Oregon Health and Science University, Portland, Oregon 97239, Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington 98101, and ProteoGenix, Inc., Portland, Oregon 97213
Received October 13, 2006
Abstract:
Cervical-vaginal fluid (CVF) is a potential rich source of biomarkers for enhancing our understanding of human parturition and pathologic conditions affecting pregnancy. In this study, we performed a comprehensive survey of the CVF proteome in pregnancy utilizing multidimensional liquid chromatography (2D-LC) coupled with mass spectrometry and gel-electrophoresis-based protein separation and identification. In total, 150 unique proteins were identified using multiple protein identification algorithms. Metabolism (32%) and immune response-related (22%) proteins are the major functional categories represented in the CVF proteome. A comparison of the CVF, serum, and amniotic fluid proteomes showed that 77 proteins are unique to CVF, while 56 and 17 CVF proteins also occur in serum and amniotic fluid, respectively. This data set provides a foundation for evaluation of these proteins as potential CVF biomarkers for noninvasive diagnosis of pregnancy-related disorders.
Keywords: vaginal fluid
pregnancy
proteome
prematurity
Cervical-vaginal fluid (CVF) is a complex biological fluid
consisting of water, electrolytes, low-molecular-weight organic
compounds (glucose, amino acids, and lipids), cells (leukocytes,
lymphocytes, and epithelial cells), and a multitude of proteins
and proteolytic enzymes that are predominantly synthesized
by the endocervix.1 CVF also contains secretions from vaginal
cells, which include mucins, defensins, complement factors,
immunogloblins, lactoferrin, and collectins.1 CVF flows over
and lubricates the entire female reproductive tract, including
the vaginal, cervical, and uterine areas. CVF forms the first line
of defense against external pathogens, signals fertility, and aids
insemination, pregnancy, and labor.1,2 CVF also contains flora
such as Lactobacilli crispatus and Lactobacilli vaginalis. Secretions from this flora impart a low pH to the CVF, which
enhances its antipathogen activity.1 Any imbalance in the
vaginal flora or invasion of external flora results in bacterial
vaginosis. In response to bacterial vaginosis, the secretion of
several cytokines such as IL-1
, IL-1
, IL-10, IL-6, and TNF-
into the CVF by the cervical and vaginal endoepithelia changes.3,4
The cytokines and other defense molecules present in CVF
also play an important role in infection, replication, and
proliferation of sexually transmitted viruses such as HIV
and Herpes Simplex Virus (HSV) in the vagina.10-12
CVF is an important potential diagnostic site to monitor
maternal and fetal health in pregnant women because of its
minimally invasive collection method compared to that for AF,
that is, amniocentesis. A comprehensive catalog of proteins
expressed in the CVF proteome could enable better insight into
the potential role of various CVF proteins that could contribute
to or reflect complications during pregnancy or vaginal pathologies. Current proteomics technology is capable of achieving this goal by permitting the identification of a significant
fraction of the proteins and peptides that are present in a
complex biological sample. The multidimensional Protein
Identification Technology (2D-LC) technique has proven to be
an effective tool to probe entire proteomes of small organisms19
and proteomes of complex biological fluids, such as human
plasma and saliva, which have a wider dynamic range of
protein abundance.20,21
Sample Collection And Processing. This study was approved
by the IRB committee at Oregon Health & Science University.
All subjects were identified prospectively and gave informed
written consent to participate in the study. Seven subjects
representing the second trimester of pregnancy (16-21 weeks),
at a mean gestational age (GA) of 18.5 weeks and a standard
deviation of ±2.3 weeks were recruited. All subjects were
asymptomatic and recruited from our outpatient office between
16 and 21 weeks gestation as they presented for prenatal care,
provided they met the inclusion criteria. Main inclusion criteria
were singleton pregnancy, intact amniotic membranes, no
evidence of cervical-vaginal infection, and a fetus without
major congenital anomaly or aneuploidy. All 7 of these subjects
delivered at term, and none of them developed preeclampsia
or gestational diabetes. CVF samples were collected by placing
2 sterile G-in, Dacron-tipped plastic applicators (Solon, Skowhegan, ME) into the posterior vaginal fornix and rotating them
for 15 s during sterile speculum examination. Following collection, protein was extracted into phosphate-buffered saline
with a protease inhibitor cocktail (Roche Diagnostics, Alameda,
CA). Samples were spun after extraction to remove any debris
and cellular material, and the supernatant was stored at -70
C. Two pooled samples (GA 16-18 and 19-21 weeks) were
prepared (n = 3 for each pool) by combining GA-matched
samples. A total of 530
g of protein from each pooled sample
was acetone-precipitated and dissolved in 10 mM Tris, pH 8.5,
for 2D-LC analysis. A total of 100
g of the remaining individual
sample was used for one-dimensional gel electrophoresis
(1D-GE).
Multidimensional Liquid Chromatography (2D-LC). A total
of 530
g of protein from each pooled sample was dried and
dissolved in 100
L of digestion buffer containing 8 M urea, 1
M Tris base, 100 mM methylamine, and 10 mM CaCl2 (pH 8.5).
Samples were reduced and alkylated by first incubating at 50
C in 12.5
L of 0.9 M dithiothreitol (DTT) for 15 min and then
in 25
L of 1.0 M iodoacetamide in dark at room temperature
for another 15 min. An additional 12.5
L of 0.9 M DTT, along
with 210
L of water and 1N NaOH, was added to the solution
to adjust its pH to 8.5. Samples were digested with 40
L of 1
mg/mL trypsin (Promega) stock solution overnight at 37
C.
Digestion was stopped with 40
L of formic acid and desalted
using C18 SepPak Plus cartridges. Digests (1 mL) were injected
onto a polysulfoethyl strong cation-exchange (SCX) column
(2.1-mm i.d. × 100 mm, 5-
m particle size and 300-Å pore size
(The Nest Group, Southborough, MA)) and fractionated using
an HPLC equipped with a UV detector and a fraction collector.
Solvent A was 10 mM potassium phosphate (pH 3) with 25%
acetonitrile (ACN), and solvent B was 10 mM potassium
phosphate (pH 3) and 350 mM KCl with 25% ACN. A 95-min
gradient at a flow rate of 200
L/min was employed for fractionation of peptides. In total, 80 fractions were collected, evaporated, and resuspended in 100
L of 0.1% TFA for desalting
using a 96-well Vydac C18 silica spin plate (The Nest Group,
Southborough, MA). Fractions were eluted in 80% ACN/0.1%
formic acid (FA), evaporated, and resuspended in 20
L of 5%
FA, and 5
L of each fraction was analyzed on a Q-Tof-2 mass
spectrometer connected to a CapLC (Waters, Milford, MA).
One-Dimensional Gel Electrophoresis (1D-GE) Analysis. A
total of 100
g of protein from an individual sample was
reduced with iodoacetamide and resolved on a Tris-tricine, 10-20% gradient SDS-PAGE gel. The gel was stained with Coomassie blue R-250. Each lane was sliced into 25 individual
bands, destained, and digested in-gel with trypsin for 24 h at
37
C. The peptides were extracted in ammonium bicarbonate
and then filtered with a 0.22-
m MultiScreen filter plate
(Millipore, Billerica, MA). Filtered solutions were dried, reconstituted in 5% formic acid, and analyzed twice (technical
replicates) on a Q-Tof-2 mass spectrometer equipped with a
CapLC (Waters, Inc., Milford, MA).
Mass Spectrometry. 2D-LC fractions and gel digests were
further separated using a Nanoease C18 75-
m i.d. × 15-cm
fused-silica capillary column (Waters Inc., Milford, MA) and a
95-min water/ACN gradient. The mass spectrometer was
calibrated using Glu1Fibrinopeptide B. An MS-MS/MS survey
method was used to acquire spectra. Masses from m/z 400 to
1500 were scanned for MS survey and masses from m/z 50 to
1900 for MS/MS. In total, 27 397 MS/MS spectra were acquired
from the 2D-LC fractions. Raw MS/MS spectra were preprocessed with ProteinLynx Global Server v.2.1 software (Waters,
Inc., Milford, MA).
Protein and Peptide Identification. Supporting Information
Figure 1 shows the protein and peptide identification workflow.
Raw MS/MS spectra from either 2D-LC samples or 1D-GE
samples were further processed by de-isotoping and centroiding the raw data. Preprocessed MS/MS spectra from different
fractions of the sample were pooled for further analysis.
Peptides present in the sample were identified by matching
pooled MS/MS spectra to a combined protein database containing known contaminants and forward and reverse entries
from the Swiss-Prot database (version 46.6) selected for human
species. Peptide identification searches were performed using
three independent search engines: TurboSequest (ThermoFinnigan, Waltham, MA), X! Tandem,24 and OpenSea.25,26
Protein identifications that had at least one unique, highly
confident (probability
0.9) peptide identification were considered likely to be present in the sample. A protein was
accepted into the comprehensive list without manual validation
if it was confidently identified in at least one of the samples
with three highly confident unique peptide hits. Proteins that
did not meet this filtering criterion were manually validated.
Manual validation was performed using all criteria listed in
reference 21, enhanced fragmentation C-terminal to aspartic
acid,27 and the presence of low-mass immonium ions (proline,
valine, isoleucine, leucine, histidine, phenylalanine, and tyrosine) whenever these residues were present in the peptide
sequence.
Human CVF was analyzed using two different proteomics techniques: 2D-LC and 1D-GE. Two pooled samples were trypsinized and subjected to SCX fractionation, resulting in a total of 40 fractions. An individual sample was fractionated using 1D-GE, and the resulting bands were subject to in-gel trypsin digestion. In total, 27 397 MS/MS spectra were collected by analyzing all fractions on a LC-ESI-qTOF mass spectrometer. All MS/MS spectra were searched using Sequest, X! Tandem, and OpenSea. Peptide identifications from all programs were assembled into protein identifications using Scaffold.
In total, 831 proteins at the single-peptide identification level were identified when the lowest possible peptide identification probability thresholds (0.2) were employed. Thirty percent of the identified proteins were false-positive identifications (reverse database entries). Several protein isoforms and proteins that were subsets of other proteins were present in the list. Furthermore, the low-scoring (peptide identification probability < 0.9) peptide identifications did not manifest the necessary characteristics to pass the manual validation criterion listed in the Materials and Methods. A large proportion (54%) of the protein hits were also single-peptide identifications. Since single-peptide protein identifications are more likely to be false-positives and, therefore, insufficient for protein quantitation and inferring pathobiological function, a peptide identification probability of 0.9 was established as a minimal criterion to consider only highly confident peptide and protein identifications. Degenerate protein identifications were grouped together and reported as one entry, and any proteins that were subsets of other proteins were removed from the analysis.
A total of 206 unique proteins from all experiments was mapped to 55% of the experimental MS/MS spectra after applying the filtering described above. Three and 15% of the identified proteins in the list are false-positive identifications and single-peptide identifications, respectively. A total of 177 proteins remained after removing contaminants such as keratins, trypsin, and bovine casein. A total of 105 proteins that had at least three unique peptide hits in at least one of the experiments was accepted without further manual validation. The remaining protein identifications were manually validated using the criteria listed in the Materials and Methods. An additional 45 proteins passed manual validation; 29 of them had at least two unique peptide hits, and 16 had a single peptide hit. This increased the number of proteins that were identified with at least two distinct peptide hits to 134, and with at least one distinct peptide hit to 150.
To ensure the reliability of protein identifications, we performed all searches with a combined database that was constructed with reverse entries of the database appended at the end of the forward sequences. The number of reverse database entries that passed all criteria for protein identification was considered to reflect the reliability of the protein identification criteria outlined in the Materials and Methods. Since none of the reverse entries met these criteria, the reliability of the protein identifications was estimated to be 100%.
MS/MS spectral counting is generally considered to be a sensitive and semiquantitative method for measuring protein abundances.28 However, homologous proteins pose a greater problem for accurate MS/MS spectral count representation due to their high sequence similarity. To avoid either inflation or deflation of MS/MS spectral counts of homologous proteins, a final level of filtering was performed to combine MS/MS spectral counts of protein homologues that share greater than 50% sequence homology. For example, squamous cell carcinoma 1 and 2 antigens share greater than 90% sequence homology. Although we have identified peptide hits that suggest the presence of both proteins in the sample, their MS/MS spectral counts were combined and represented as a single entry. Proteins that were combined under this criterion were IGHA1 and IGHA2; IGHG1, IGHG2, and IGHG4; SCCA1 and SCAA2; and SPR2A, SPR2B, and SPR2D. MS/MS spectral counts of peptides common to proteins that do not share high sequence homology were pulled toward the protein that was considered most likely (greater number of peptide hits) to be present in the sample. Finally, a combined MS/MS spectral count for each protein was established by combining the respective MS/MS spectral counts of the protein in all experiments. The combined MS/MS spectral count was normalized by the total number (12 827) of MS/MS spectra that were matched to noncontaminant proteins at a single-peptide probability threshold of 0.9 in all experiments. The normalized spectral counts are not strictly quantitative, but they can be used to gauge the relative abundance of the proteins present in a sample with respect to each other.
The final 134 proteins that had at least two unique peptide
hits and passed manual validation are listed in Table 1
by their
decreasing order of normalized MS/MS spectral counts. The
16 proteins that had a single peptide hit and passed the manual
validation are listed in Supporting Information Table 1 by their
decreasing order of combined MS/MS spectral counts. Proteins
listed in the tables are functionally annotated based on the
classification from the Database for Annotation, Visualization
and Integrated Discovery (DAVID).29
The CVF proteins found in this study were cross-referenced
with the HUPO plasma proteome20,30 and the AF proteome.31-33
The 2D-LC technique is known to provide enhanced fractionation compared to traditional gel-based electrophoresis methods. Figure 1 shows the number of unique peptides identified per SCX fraction from the 2D-LC fractionation. Clearly, the enhanced fractionation of the technique, when coupled with RP-HPLC, contributed to the identification of a greater number of unique peptides per SCX fraction and, overall, a large number of protein identifications in the sample.
Recent studies have shown that a MS/MS dataset can be thoroughly characterized using multiple search engines to identify the peptides in that data set.22 When different search engines are used to identify peptides in a data set, they identify different sets of MS/MS spectra due to the difference in heuristics that are encoded in the corresponding search engines. Thus, a combination of different search engine results on the same data set gives a more comprehensive list of peptide identifications. In this study, we have used three different search engines to identify the peptides present in the samples: Sequest, X! Tandem, and OpenSea. Using this combinatorial approach, we were able to identify 59% of the acquired MS/MS spectra in one of the 2D-LC experiments. The breakdown of percentages of spectral identifications (above the score cutoffs of the corresponding programs) between the three programs (Figure 2a) shows that only 38% of spectra were identified by all three programs, whereas 22% of spectra were identified uniquely by only one of the programs. Interestingly, 15% of the spectra were identified solely by the OpenSea search engine. This is due to the ability of OpenSea to identify spectra with missing fragment ions and unexpected sequence modifications. The total number of candidate proteins identified in the sample was also increased due to the combinatorial search technique. Among a total of 118 candidate protein identifications as shown in Figure 2b, 66% were identified by all three programs, whereas 13% were identified uniquely by only one of the programs. Thus, the combinatorial search technique employed in this study identified more peptide and candidate protein identifications from the data sets.
The composition of maternal CVF changes with gestational age and vaginal health. The overlap of proteins identified in two biological replicates from 2D-LC experiments is shown in Figure 3. Sixty-nine percent of the proteins were identified in both biological replicates, whereas 31% of the proteins were identified solely in one of the replicates. This was not unexpected, since GA-dependent changes in the cervix play a significant biological role in the process of labor and delivery. The random sampling of low-abundance proteins by the mass spectrometer might also have contributed to the above-mentioned difference. Among 65 proteins that were identified by 1D-GE technical replicates, 69% were identified in both replicates, whereas 31% were identified uniquely in one of the replicates. This underscores the importance of having biological and technical replicates when characterizing proteomes. The overall increase in the number of protein identifications with the addition of experiments to the analysis is summarized in Figure 4. A total of 40 proteins was identified by our protein identification criteria when using a single 1D-GE experiment. An increase of 15, 69, and 16 protein identifications was observed when a single 1D-GE technical replicate, the 2D-LC experiment, and its corresponding biological replicate were added to the analysis, respectively. This is the first comprehensive proteomics study that has employed a variety of analysis programs, technical replicates, biological replicates, and experimental methods to characterize the human CVF proteome.
The combinatorial proteomics approach applied in this study
characterized the proteomic composition of CVF during pregnancy by uncovering a large number of proteins that were not
previously known to be present in CVF. Table 1 and Supporting
Information Table 1 list a comprehensive set of proteins present
in CVF that are involved in homeostasis of the reproductive
area and fetal protection. The tryptic peptide profile of the
proteins listed in Table 1 is shown in Figure 5. Over 89% of the
proteins had at least two unique peptide identifications. The
peptide profile also shows that CVF contains a variety of
proteins that have a wide range of tryptic peptide yields. Figure
6 shows the functional classification of the CVF proteome
during pregnancy. The major functional groups in CVF are
immune and defense-related molecules (such as calgranulins
A and B) and metabolic molecules (ranging from proteases such
as cathepsins B and G to chaperones, like heat shock protein
90-
(HSP 90-
).
The immunoresponse proteins found in this study fell into
three categories: proinflammatory response molecules, anti-inflammatory response molecules, and antimicrobial molecules. Apart from commonly occurring immunogloblins, the
most notable proinflammatory response molecules found in
CVF are two calcium-binding proteins from the S100 family,
calgranulins A and B. These proteins form a heterodimer
mediated by Ca+2 ions and are commonly implicated in both
acute-phase and chronic inflammation responses.34 The relative
abundance of these proteins in a control CVF sample, when
compared to albumin (Table 1), suggests their vital role in
fighting vaginal infections. It is also interesting to note that
calgranulins A and B are also found in the intra-amniotic fluid
during intra-amniotic infection,35,36
Antimicrobial proteins play an important role in preventing
infection of the vagina from bacterial and fungal pathogens.
Confirming previous reports,40 we have detected neutrophil
defensin 1 (defensin family) and lactotransferrin in CVF, which
are known to have antimicrobial properties and may protect
the vagina from infections like Neisseriae gonorrhoeae and
HSV.40 Additionally, we have also detected several proteins from
the histone family (H4, H2A, H2B, and H1.2). Traditionally,
histones are considered to be intracellular proteins that are
involved in chromatin arrangement inside the nucleus. However, recent studies have indicated that secreted neutrophil
extracellular traps (NETs) contain histones,41,42
A major proportion (32%) of proteins found in this study are
involved in various metabolic activities (Figure 6) like inflammatory regulation, protein degradation, and protease inhibition. Among the inflammatory regulation proteins we have
observed are HSP90-A, bradykinin (kininogen 1 precursor), and
kallikrein (kallikrein 11 and 13 precursors). HSP90-A has been
recently reported to be involved in cell-mediated activation of
the proinflammatory bradykinin-kallikrein complex.47 Such cell-mediated immunity has been shown to be a key factor in
defense against pathogens that infect the lower female genital
tract.48 The balance between proteases and protease inhibitors
is critical for maintenance of healthy tissue, and imbalances
often lead to serious cervical epithelial pathology. Among
several proteases and antiproteases we observed in CVF, one
of the interesting pairs is cathepsin B and
1 antitrypsin (A1AT).
In cases of cervical carcinoma, the levels of cathepsin B in CVF
are elevated, while the levels of A1AT are unchanged.49-51
Apart from immune response and metabolic proteins, we also found proteins that aid in cell differentiation (11%), transport (9%), cell organization (8%), enzyme regulation (6%), signal transduction (3%), and cell proliferation (3%). A protein could have multiple functions depending on its environment. For example, according to the DAVID functional annotation tool, histones are classified as proteins involved in cell organization. However, as discussed earlier, they also have antimicrobial properties when secreted outside the cell. Thus, the role of many of the other proteins found in CVF during pregnancy is still unclear and warrants further investigation.
Prior to this study, the relative abundance of proteins that
are native to CVF during pregnancy was largely unknown. The
proteins in Table 1 are arranged by their decreasing order of
normalized spectral counts. The generic ratio of IgG/IgA protein
abundance in our analysis matches well with previous studies.52
Interestingly, the protein abundance profile of CVF and serum
differ significantly. Among the top 15 abundant CVF proteins,
six proteins are known to be either non-native and/or low-abundance in serum (squamous cell carcinoma antigens,
calgranulins A and B, small proline rich protein 3, fatty acid-binding protein epidermal, and mucin 5B).20,21,53,54
A quantitative analysis of proteome overlap between the AF,
serum, and CVF was carried out, and the last column in Table
1 and Supporting Information Table 1 denotes the CVF proteins
that were also observed in AF (A) and serum (S). Active serum
transport and local synthesis are known to be the sources of
serum proteins in the cervix.55 Confirming this, we found the
sIgA complex, which is locally synthesized in the cervix.56 In
addition, we detected several abundant serum proteins20,30,55
like serum albumin, alpha-1-antitrypsin precursor, apolipoprotein A1 precursor, serotransferrin, lactotransferrin, apolipoprotein A1 precursor,
-2-HS glycoprotein, Ig
1, 2, and 4
chain C regions, and
-2-glycopotein 1 precursor in CVF. It is
interesting to note that we also detected several proteins in
CVF, like small proline-rich protein 3, CD59 glycoprotein
precursor, cystatin A, cystatin B, cornifin A, involucrin, and
thioredoxin, which are found in AF but not serum. Parallel
secretions of the chorionic-decidual membrane could be a
source of these proteins in CVF. Among the proteins that were
present in all three biological fluids, A1AT and ceruloplasmin
(copper transporter) are known to have diagnostic importance.
The abundance ceruloplasmin in maternal vaginal secretions
and serum has been inversely correlated with incidence of
premature rupture of membranes (PROM),17,57 and increased
expression of A1AT in serum has been correlated with cervical
cancer.51 This suggests that serial assessment of easily accessible
body fluids like CVF or serum could be used in maternal and
fetal health diagnostics. However, a caveat of the above
conclusion is that the HUPO plasma proteome used in the
comparison consists of both nonmaternal and maternal proteins. A separate comparison of the CVF proteome with second-trimester maternal serum proteome consisting of 392 proteins
(data not shown) yielded 53 common proteins.
In summary, we have employed a combinatorial proteomics approach using multiple biological replicates, multiple experimental techniques for protein and peptide fractionation, and multiple search engines for data mining to characterize the CVF proteome. This multiplexed approach identified a large set of proteins that were not previously known to be present in CVF. The functional classification of the CVF proteome suggested the presence of a wide variety of cytokine response proteins that play a vital role in fighting pathogens and protecting the fetus. A quantitative analysis of proteome overlap between serum, AF, and CVF identified several serum and AF proteins as present in the CVF during pregnancy. Differential abundance of some of those proteins has already been linked to PROM and cervical cancer. This initial characterization of the CVF proteome involved a small sample size covering limited GA. Further investigation with serial first-, second-, and third-trimester sampling could enhance the proteome coverage and provide potential GA-dependent profiles. Large-scale, high-throughput proteomics technologies are vital to further our understanding of the CVF proteome during pregnancy and its development as a potential diagnostic tool for monitoring maternal and fetal health.
This work has been supported in part by ProteoGenix, Inc. Oregon Health & Science University and Drs. Gravett, Roberts, and Nagalla all have a significant financial interest in ProteoGenix, Inc., a company that may have a commercial interest in the results of this research and technology. This potential conflict of interest has been reviewed and a management plan approved by the OHSU Conflict of Interest in Research Committee.
Figure showing the protein and peptide identification workflow; table listing the single-peptide protein identifications of the human CVF proteome. This material is available free of charge via the Internet at http://pubs.acs.org.
* To whom correspondence should be addressed. E-mail, nagallas@ohsu.edu; tel, 503-494-1928; fax, 503-494-4821.
Department of Pediatrics, Oregon Health and Science University.
Department of Obstetrics and Gynecology, Oregon Health and Science
University.
ProteoGenix, Inc.
University of Washington.
1. Blandau, R. J.; Moghissi, K. S. The Biology of the Cervix; University of Chicago Press: Chicago, IL, 1973; p xi, p 450.
2. Bigelow, J. L.; Dunson, D. B.; Stanford, J. B.; Ecochard, R.; Gnoth,
C.; Colombo, B. Mucus observations in the fertile window: a
better predictor of conception than timing of intercourse. Hum.
Reprod. 2004, 19 (4), 889-92.
3. Mattsby-Baltzer, I.; Platz-Christensen, J. J.; Hosseini, N.; Rosen,
P. IL-1beta, IL-6, TNFalpha, fetal fibronectin, and endotoxin in
the lower genital tract of pregnant women with bacterial vaginosis. Acta Obstet. Gynecol. Scand. 1998, 77 (7), 701-6.
4. Eschenbach, D. A.; Davick, P. R.; Williams, B. L.; Klebanoff, S. J.;
Young-Smith, K.; Critchlow, C. M.; Holmes, K. K. Prevalence of
hydrogen peroxide-producing Lactobacillus species in normal
women and women with bacterial vaginosis. J. Clin. Microbiol.
1989, 27 (2), 251-6.
5. Mikamo, H.; Sato, Y.; Hayasaki, Y.; Kawazoe, K.; Izumi, K.; Ito,
K.; Yamada, Y.; Tamaya, T. Intravaginal bacterial flora in patients
with uterine cervical cancer. High incidence of detection of
Gardnerella vaginalis. J. Infect. Chemother. 1999, 5 (2), 82-5.
6. Ness, R. B.; Kip, K. E.; Hillier, S. L.; Soper, D. E.; Stamm, C. A.;
Sweet, R. L.; Rice, P.; Richter, H. E. A cluster analysis of bacterial
vaginosis-associated microflora and pelvic inflammatory disease.
Am. J. Epidemiol. 2005, 162 (6), 585-90.
7. Haggerty, C. L.; Hillier, S. L.; Bass, D. C.; Ness, R. B. Bacterial
vaginosis and anaerobic bacteria are associated with endometritis. Clin. Infect. Dis. 2004, 39 (7), 990-5.
8. Morris, M.; Nicoll, A.; Simms, I.; Wilson, J.; Catchpole, M. Bacterial
vaginosis: a public health review. BJOG 2001, 108 (5), 439-50.
9. Gravett, M. G.; Nelson, H. P.; DeRouen, T.; Critchlow, C.;
Eschenbach, D. A.; Holmes, K. K. Independent associations of
bacterial vaginosis and Chlamydia trachomatis infection with
adverse pregnancy outcome. JAMA, J. Am. Med. Assoc. 1986, 256
(14), 1899-903.
10. Poli, G.; Fauci, A. S. The effect of cytokines and pharmacologic
agents on chronic HIV infection. AIDS Res. Hum. Retroviruses
1992, 8 (2), 191-7.
11. Zara, F.; Nappi, R. E.; Brerra, R.; Migliavacca, R.; Maserati, R.;
Spinillo, A. Markers of local immunity in cervico-vaginal secretions of HIV infected women: implications for HIV shedding. Sex
Transm. Infect. 2004, 80 (2), 108-12.
12. John, M.; Keller, M. J.; Fam, E. H.; Cheshenko, N.; Hogarty, K.;
Kasowitz, A.; Wallenstein, S.; Carlucci, M. J.; Tuyama, A. C.; Lu,
W.; Klotman, M. E.; Lehrer, R. I.; Herold, B. C. Cervicovaginal
secretions contribute to innate resistance to herpes simplex virus
infection. J. Infect. Dis. 2005, 192 (10), 1731-40.
13. Venkataraman, N.; Cole, A. L.; Svoboda, P.; Pohl, J.; Cole, A. M.
Cationic polypeptides are required for anti-HIV-1 activity of
human vaginal fluid. J. Immunol. 2005, 175 (11), 7560-7.
14. Maher, D.; Wu, X.; Schacker, T.; Horbul, J.; Southern, P. HIV
binding, penetration, and primary infection in human cervicovaginal tissue. Proc. Natl. Acad. Sci. U.S.A. 2005, 102 (32), 11504-9.
15. Quinones-Mateu, M. E.; Lederman, M. M.; Feng, Z.; Chakraborty,
B.; Weber, J.; Rangel, H. R.; Marotta, M. L.; Mirza, M.; Jiang, B.;
Kiser, P.; Medvik, K.; Sieg, S. F.; Weinberg, A. Human epithelial
beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003, 17
(16), F39-48.
16. Helmig, B. R.; Romero, R.; Espinoza, J.; Chaiworapongsa, T.;
Bujold, E.; Gomez, R.; Ohlsson, K.; Uldbjerg, N. Neutrophil
elastase and secretory leukocyte protease inhibitor in prelabor
rupture of membranes, parturition and intra-amniotic infection.
J. Matern.-Fetal Neonat. Med. 2002, 12 (4), 237-46.
17. Ogino, M.; Hiyamuta, S.; Takatsuji-Okawa, M.; Tomooka, Y.;
Minoura, S. Establishment of a prediction method for premature
rupture of membranes in term pregnancy using active ceruloplasmin in cervicovaginal secretion as a clinical marker. J. Obstet.
Gynaecol. Res. 2005, 31 (5), 421-6.
18. Swamy, G. K.; Simhan, H. N.; Gammill, H. S.; Heine, R. P. Clinical
utility of fetal fibronectin for predicting preterm birth. J. Reprod.
Med. 2005, 50 (11), 851-6.
19. Washburn, M. P.; Wolters, D.; Yates, J. R., III. Large-scale analysis
of the yeast proteome by multidimensional protein identification
technology. Nat. Biotechnol. 2001, 19 (3), 242-7.
20. Anderson, N. L.; Polanski, M.; Pieper, R.; Gatlin, T.; Tirumalai, R.
S.; Conrads, T. P.; Veenstra, T. D.; Adkins, J. N.; Pounds, J. G.;
Fagan, R.; Lobley, A. The human plasma proteome: a nonredundant list developed by combination of four separate sources.
Mol. Cell. Proteomics 2004, 3 (4), 311-26.
21. Wilmarth, P. A.; Riviere, M. A.; Rustvold, D. L.; Lauten, J. D.;
Madden, T. E.; David, L. L. Two-dimensional liquid chromatography study of the human whole saliva proteome. J. Proteome
Res. 2004, 3 (5), 1017-23.
22. Resing, K. A.; Meyer-Arendt, K.; Mendoza, A. M.; Aveline-Wolf,
L. D.; Jonscher, K. R.; Pierce, K. G.; Old, W. M.; Cheung, H. T.;
Russell, S.; Wattawa, J. L.; Goehle, G. R.; Knight, R. D.; Ahn, N. G.
Improving reproducibility and sensitivity in identifying human
proteins by shotgun proteomics. Anal. Chem. 2004, 76 (13), 3556-68.
23. Setsuko Komatsu, X. Z. Naoki Tanaka. Comparision of two
proteomics techniques used to identify proteins regulated by
gibberellin in rice. J. Proteome Res. 2006, 5 (2), 270-6.
24. Fenyo, D.; Beavis, R. C. A method for assessing the statistical
significance of mass spectrometry-based protein identifications
using general scoring schemes. Anal. Chem. 2003, 75 (4), 768-74.
25. Searle, B. C.; Dasari, S.; Turner, M.; Reddy, A. P.; Choi, D.;
Wilmarth, P. A.; McCormack, A. L.; David, L. L.; Nagalla, S. R.
High-throughput identification of proteins and unanticipated
sequence modifications using a mass-based alignment algorithm
for MS/MS de novo sequencing results. Anal. Chem. 2004, 76 (8),
2220-30.
26. Searle, B. C.; Dasari, S.; Wilmarth, P. A.; Turner, M.; Reddy, A. P.;
David, L. L.; Nagalla, S. R. Identification of protein modifications
using MS/MS de novo sequencing and the OpenSea alignment
algorithm. J. Proteome Res. 2005, 4 (2), 546-54.
27. Gu, C.; Tsaprailis, G.; Breci, L.; Wysocki, V. H. Selective gas-phase
cleavage at the peptide bond C-terminal to aspartic acid in fixed-charge derivatives of Asp-containing peptides. Anal. Chem. 2000,
72 (23), 5804-13.
28. Old, W. M.; Meyer-Arendt, K.; Aveline-Wolf, L.; Pierce, K. G.;
Mendoza, A.; Sevinsky, J. R.; Resing, K. A.; Ahn, N. G. Comparison
of label-free methods for quantifying human proteins by shotgun
proteomics. Mol. Cell. Proteomics. 2005, 4
29. Dennis, G., Jr.; Sherman, B. T.; Hosack, D. A.; Yang, J.; Gao, W.;
Lane, H. C.; Lempicki, R. A. DAVID: database for annotation,
visualization, and integrated discovery. GenomeBiology 2003, 4
(5), P3.
30. States, D. J.; Omenn, G. S.; Blackwell, T. W.; Fermin, D.; Eng, J.;
Speicher, D. W.; Hanash, S. M. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO
plasma proteome collaborative study. Nat. Biotechnol. 2006, 24
(3), 333-8.
31. Park, S. J.; Yoon, W. G.; Song, J. S.; Jung, H. S.; Kim, C. J.; Oh, S.
Y.; Yoon, B. H.; Jung, G.; Kim, H. J.; Nirasawa, T. Proteome
analysis of human amnion and amniotic fluid by two-dimensional electrophoresis and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proteomics 2006, 6
(1), 349-63.
32. Michel, P. E.; Crettaz, D.; Morier, P.; Heller, M.; Gallot, D.; Tissot,
J. D.; Reymond, F.; Rossier, J. S. Proteome analysis of human
plasma and amniotic fluid by Off-Gel isoelectric focusing followed
by nano-LC-MS/MS. Electrophoresis 2006, 27 (5-6), 1169-81.
33. Michaels, J.-E. A.; Dasari, S.; Pereira, L.; Reddy, A. P.; Lapidus, J.
A.; Lu, X.; Jacob, T.; Thomas, A.; Rodland, M.; Roberts, C. T., Jr.;
Gravett, M. G.; Nagalla, S. R. Comprehensive proteomic analysis
of the human amniotic fluid proteome: gestational age-dependent changes. J. Proteome Res. 2007, 6, 1277-1285.
34. Kerkhoff, C.; Klempt, M.; Sorg, C. Novel insights into structure
and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim.
Biophys. Acta 1998, 1448 (2), 200-11.
35. Gravett, M. G.; Novy, M. J.; Rosenfeld, R. G.; Reddy, A. P.; Jacob,
T.; Turner, M.; McCormack, A.; Lapidus, J. A.; Hitti, J.; Eschenbach, D. A.; Roberts, C. T. Jr.; Nagalla, S. R. Diagnosis of intra-amniotic infection by proteomic profiling and identification of
novel biomarkers. JAMA, J. Am. Med. Assoc. 2004, 292 (4), 462-9.
36. Ruetschi, U.; Rosen, A.; Karlsson, G.; Zetterberg, H.; Rymo, L.;
Hagberg, H.; Jacobsson, B. Proteomic analysis using protein chips
to detect biomarkers in cervical and amniotic fluid in women
with intra-amniotic inflammation. J. Proteome Res. 2005, 4 (6),
2236-42.
37. Lachapelle, M. H.; Miron, P.; Hemmings, R.; Roy, D. C. Endometrial, T, B, and NK cells in patients with recurrent spontaneous
abortion. Altered profile and pregnancy outcome. J. Immunol.
1996, 156 (10), 4027-34.
38. Borzychowski, A. M.; Croy, B. A.; Chan, W. L.; Redman, C. W.;
Sargent, I. L. Changes in systemic type 1 and type 2 immunity in
normal pregnancy and pre-eclampsia may be mediated by
natural killer cells. Eur. J. Immunol. 2005, 35 (10), 3054-63.
39. Genc, M. R.; Karasahin, E.; Onderdonk, A. B.; Bongiovanni, A.
M.; Delaney, M. L.; Witkin, S. S. Association between vaginal 70-kd heat shock protein, interleukin-1 receptor antagonist, and
microbial flora in mid trimester pregnant women. Am. J. Obstet.
Gynecol. 2005, 192 (3), 916-21.
40. MasCasullo, V.; Fam, E.; Keller, M. J.; Herold, B. C. Role of mucosal
immunity in preventing genital herpes infection. Viral Immunol.
2005, 18 (4), 595-606.
41. Brinkmann, V.; Reichard, U.; Goosmann, C.; Fauler, B.; Uhlemann, Y.; Weiss, D. S.; Weinrauch, Y.; Zychlinsky, A. Neutrophil
extracellular traps kill bacteria. Science 2004, 303 (5663), 1532-5.
42. Buchanan, J. T.; Simpson, A. J.; Aziz, R. K.; Liu, G. Y.; Kristian, S.
A.; Kotb, M.; Feramisco, J.; Nizet, V. DNase expression allows the
pathogen group A Streptococcus to escape killing in neutrophil
extracellular traps. Curr. Biol. 2006, 16 (4), 396-400.
43. Silphaduang, U.; Hincke, M. T.; Nys, Y.; Mine, Y. Antimicrobial
proteins in chicken reproductive system. Biochem. Biophys. Res.
Commun. 2006, 340 (2), 648-55.
44. Jacobsen, F.; Baraniskin, A.; Mertens, J.; Mittler, D.; Mohammadi-Tabrisi, A.; Schubert, S.; Soltau, M.; Lehnhardt, M.; Behnke, B.;
Gatermann, S.; Steinau, H. U.; Steinstraesser, L. Activity of histone
H1.2 in infected burn wounds. J. Antimicrob. Chemother. 2005,
55 (5), 735-41.
45. Kim, H. S.; Cho, J. H.; Park, H. W.; Yoon, H.; Kim, M. S.; Kim, S.
C. Endotoxin-neutralizing antimicrobial proteins of the human
placenta. J. Immunol. 2002, 168 (5), 2356-64.
46. Rose, F. R.; Bailey, K.; Keyte, J. W.; Chan, W. C.; Greenwood, D.;
Mahida, Y. R. Potential role of epithelial cell-derived histone H1
proteins in innate antimicrobial defense in the human gastrointestinal tract. Infect. Immun. 1998, 66 (7), 3255-63.
47. Joseph, K.; Tholanikunnel, B. G.; Kaplan, A. P. Heat shock protein
90 catalyzes activation of the prekallikrein-kininogen complex in
the absence of factor XII. Proc. Natl. Acad. Sci. U.S.A. 2002, 99
(2), 896-900.
48. Pudney, J.; Quayle, A. J.; Anderson, D. J. Immunological microenvironments in the human vagina and cervix: mediators of cellular
immunity are concentrated in the cervical transformation zone.
Biol. Reprod. 2005, 73 (6), 1253-63.
49. Bhuvarahamurthy, V.; Govindasamy, S. Extracellular matrix
components and proteolytic enzymes in uterine cervical carcinoma. Mol. Cell. Biochem. 1995, 144 (1), 35-43.
50. Makarewicz, R.; Drewa, G.; Szymanski, W.; Skonieczna-Makarewicz, I. Cathepsin B in predicting the extent of the cervix
carcinoma. Neoplasma 1995, 42 (1), 21-4.
51. Benitez-Bribiesca, L.; Freyre-Horta, R.; Gallegos-Vargas, G. Protease and antiprotease concentrations in serum and vaginal fluid
of patients with carcinoma of the cervix. Arch. Invest. Med. 1980,
11 (4), 523-45.
52. Mestecky, J.; Moldoveanu, Z.; Russell, M. W. Immunologic
uniqueness of the genital tract: challenge for vaccine development. Am. J. Reprod. Immunol. 2005, 53 (5), 208-14.
53. Qin, S.; Ferdinand, A. S.; Richie, J. P.; O'Leary, M. P.; Mok, S. C.;
Liu, B. C. Chromatofocusing fractionation and two-dimensional
difference gel electrophoresis for low abundance serum proteins.
Proteomics 2005, 5 (12), 3183-92.
54. Katz, A. B.; Taichman, L. B. A partial catalog of proteins secreted
by epidermal keratinocytes in culture. J. Invest. Dermatol. 1999,
112 (5), 818-21.
55. Bard, E.; Riethmuller, D.; Biichle, S.; Meillet, D.; Pretet, J. L.;
Mougin, C.; Seilles, E. Validation of a high sensitive immunoenzymatic assay to establish the origin of immunoglobulins in
female genital secretions. J. Immunoassay Immunochem. 2002,
23 (2), 145-62.
56. Hocini, H.; Barra, A.; Belec, L.; Iscaki, S.; Preud'homme, J. L.; Pillot,
J.; Bouvet, J. P. Systemic and secretory humoral immunity in the
normal human vaginal tract. Scand. J. Immunol. 1995, 42 (2),
269-74.
57. Kiilholma, P.; Gronroos, M.; Erkkola, R.; Pakarinen, P.; Nanto, V.
The role of calcium, copper, iron and zinc in preterm delivery
and premature rupture of fetal membranes. Gynecol. Obstet.
Invest. 1984, 17 (4), 194-201.
58. Gasteiger, E.; Gattiker, A.; Hoogland, C.; Ivanyi, I.; Appel, R. D.;
Bairoch, A. ExPASy: The proteomics server for in-depth protein
knowledge and analysis. Nucleic Acids Res. 2003, 31 (13), 3784-8.![]()
|
Swiss-Prot acc. no.a |
protein description |
pIb |
MWc |
functiond |
normalized spectral counte |
AF/Serumf |
|
P02768 |
Serum albumin precursor |
5.43 |
39.30 |
Transport |
18.84 |
A, S |
|
P01857, P01859, P01861 |
Ig gamma-1 chain C region, Ig gamma-2 chain C region, Ig gamma-4 chain C region |
8.46, 7.66, 7.18 |
36.08, 35.9, 35.9 |
Immune Response |
10.35 |
A, S |
|
Q9UBC9 |
Small proline-rich protein 3 |
8.86 |
18.10 |
Cell Differentiation |
8.6 |
A |
|
P29508, P48594 |
Squamous cell carcinoma antigen 1, Squamous cell carcinoma antigen 2 |
6.35, 5.86 |
44.5, 44.8 |
Metabolism |
6.3 |
|
|
P06702 |
Calgranulin B |
5.90 |
85.60 |
Immune Response |
5.82 |
A,S |
|
P07355 |
Annexin A2 |
4.69 |
55.30 |
Cell Differentiation |
5.33 |
A, S |
|
P04083 |
Annexin A1 |
6.96 |
11.10 |
Immune Response |
4.28 |
A |
|
Q01469 |
Fatty acid-binding protein, epidermal |
6.82 |
15.00 |
Metabolism |
3.97 |
|
|
P01834 |
Ig kappa chain C region |
5.58 |
11.60 |
Immune Response |
3.79 |
A, S |
|
P02787 |
Serotransferrin precursor |
5.22 |
51.20 |
Transport |
2.82 |
A, S |
|
P05109 |
Calgranulin A |
5.98 |
22.80 |
Immune Response |
1.78 |
A, S |
|
Q9HC84 |
Mucin-5B precursor |
6.24 |
587.60 |
Transport |
1.4 |
A |
|
P04080 |
Cystatin B |
8.39 |
39.30 |
Enzyme Regulator |
1.09 |
A |
|
P07476 |
Involucrin |
7.56 |
38.40 |
Cell Differentiation |
1.08 |
A |
|
P01040 |
Cystatin A |
5.38 |
11.00 |
Enzyme Regulator |
1.04 |
A, S |
|
P35321 |
Cornifin A |
8.85 |
9.90 |
Cell Differentiation |
1.03 |
A |
|
Q09666 |
Neuroblast differentiation associated protein AHNAK |
6.29 |
312.30 |
Cell Differentiation |
1 |
|
|
P01842 |
Ig lambda chain C regions |
6.91 |
11.20 |
Immune Response |
0.97 |
A, S |
|
P30740 |
Leukocyte elastase inhibitor |
5.90 |
42.70 |
Enzyme Regulator |
0.94 |
|
|
P05164 |
Myeloperoxidase precursor |
6.51 |
10.80 |
Immune Response |
0.84 |
|
|
P02788 |
Lactotransferrin precursor |
6.70 |
75.10 |
Immune Response |
0.82 |
A, S |
|
P80188 |
Neutrophil gelatinase-associated lipocalin precursor |
9.02 |
20.50 |
Transport |
0.81 |
A, S |
|
P01009 |
Alpha-1-antitrypsin precursor |
5.37 |
44.30 |
Immune Response |
0.76 |
A, S |
|
P61626 |
Lysozyme C precursor |
9.28 |
14.70 |
Metabolism |
0.76 |
A |
|
P01876, P01877 |
Ig alpha-1 chain C region, Ig alpha-2 chain C region |
6.08, 5.71 |
37.6, 36.5 |
Immune Response |
0.73 |
A, S |
|
P04792 |
Heat-shock protein beta-1 |
8.58 |
35.90 |
Metabolism |
0.73 |
|
|
P10599 |
Thioredoxin |
5.44 |
23.20 |
Metabolism |
0.72 |
A |
|
P62988 |
Ubiquitin |
6.56 |
8.60 |
Metabolism |
0.65 |
|
|
P01833 |
Polymeric-immunoglobulin receptor precursor |
5.59 |
83.30 |
Signal Transduction |
0.47 |
A |
|
P12429 |
Annexin A3 |
5.37 |
70.90 |
Enzyme Regulator |
0.44 |
|
|
Q8TDL5 |
Long palate, lung and nasal epithelium protein 1 |
6.69 |
50.20 |
Function Not Assigned |
0.44 |
|
|
P00450 |
Ceruloplasmin precursor |
5.41 |
120.00 |
Transport |
0.43 |
A, S |
|
P35326, P35325, P22532 |
Small proline-rich protein 2A, Small proline-rich protein 2B, Small proline-rich protein 2D |
8.81, 8.81, 8.77 |
8, 7.97, 7.9 |
Cell Differentiation |
0.41 |
|
|
P60709 |
Actin, cytoplasmic 1 |
5.29 |
41.60 |
Cell Organization |
0.38 |
A, S |
|
P01011 |
Alpha-1-antichymotrypsin precursor |
5.33 |
47.60 |
Immune Response |
0.36 |
A, S |
|
P22528 |
Cornifin B |
8.85 |
9.90 |
Cell Differentiation |
0.34 |
|
|
P00738 |
Haptoglobin precursor |
6.13 |
45.20 |
Metabolism |
0.3 |
A, S |
|
P62328 |
Thymosin beta-4 |
5.02 |
4.90 |
Cell Organization |
0.3 |
A |
|
P18510 |
Interleukin-1 receptor antagonist protein precursor |
5.51 |
123.60 |
Immune Response |
0.27 |
|
|
P01024 |
Complement C3 precursor |
6.02 |
187.00 |
Immune Response |
0.24 |
A, S |
|
P07737 |
Profilin-1 |
4.62 |
68.40 |
Cell Organization |
0.22 |
A |
|
P02790 |
Hemopexin precursor |
8.50 |
78.10 |
Transport |
0.21 |
A, S |
|
P14780 |
Matrix metalloproteinase-9 precursor |
5.18 |
9.00 |
Metabolism |
0.21 |
|
|
P04406 |
Glyceraldehyde-3-phosphate dehydrogenase, liver |
9.30 |
52.10 |
Metabolism |
0.2 |
S |
|
P15924 |
Desmoplakin |
5.95 |
69.20 |
Cell Differentiation |
0.2 |
S |
|
P08107 |
Heat shock 70 kDa protein 1 |
4.94 |
84.50 |
Metabolism |
0.19 |
|
|
Q9NQ38 |
Serine protease inhibitor Kazal-type 5 precursor |
8.50 |
120.70 |
Immune Response |
0.19 |
|
|
P12724 |
Eosinophil cationic protein precursor |
5.63 |
36.20 |
Metabolism |
0.18 |
|
|
P04279 |
Semenogelin-1 precursor |
6.64 |
38.60 |
Cell Differentiation |
0.17 |
S |
|
O60437 |
Periplakin |
5.44 |
204.50 |
Function Not Assigned |
0.16 |
|
|
P09211 |
Glutathione S-transferase P |
5.06 |
53.50 |
Metabolism |
0.16 |
|
|
P02749 |
Beta-2-glycoprotein I precursor |
8.37 |
36.20 |
Immune Response |
0.15 |
A, S |
|
P07108 |
Acyl-CoA-binding protein |
6.99 |
47.00 |
Transport |
0.15 |
|
|
P59665 |
Neutrophil defensin 1 precursor |
6.54 |
10.20 |
Immune Response |
0.15 |
S |
|
O60235 |
Transmembrane protease, serine 11D precursor |
8.69 |
46.20 |
Metabolism |
0.13 |
|
|
P03973 |
Antileukoproteinase 1 precursor |
6.43 |
49.30 |
Enzyme Regulator |
0.13 |
A |
|
P04075 |
Fructose-bisphosphate aldolase A |
6.95 |
59.60 |
Enzyme Regulator |
0.13 |
|
|
P14923 |
Junction plakoglobin |
5.69 |
78.40 |
Transport |
0.13 |
S |
|
P62805 |
Histone H4 |
11.36 |
11.20 |
Cell Organization |
0.12 |
|
|
P62937 |
Peptidyl-prolyl cis-trans isomerase A |
7.82 |
17.90 |
Metabolism |
0.12 |
A |
|
Q02383 |
Semenogelin-2 precursor |
9.04 |
62.90 |
Cell Differentiation |
0.12 |
S |
|
P02774 |
Vitamin D-binding protein precursor |
5.67 |
66.40 |
Transport |
0.11 |
A, S |
|
P07858 |
Cathepsin B precursor |
8.47 |
14.90 |
Metabolism |
0.11 |
|
|
P24158 |
Myeloblastin precursor |
7.79 |
24.20 |
Metabolism |
0.11 |
|
|
Swiss-Prot acc. no.a |
protein description |
pIb |
MWc |
functiond |
normalized spectral counte |
AF/Serumf |
|
P00441 |
Superoxide dismutase |
5.70 |
15.80 |
Cell Differentiation |
0.1 |
|
|
P02763 |
Alpha-1-acid glycoprotein 1 precursor |
5.00 |
21.50 |
Immune Response |
0.1 |
A, S |
|
P02765 |
Alpha-2-HS-glycoprotein precursor |
5.00 |
21.50 |
Signal Transduction |
0.1 |
A, S |
|
P04040 |
Catalase |
5.55 |
54.30 |
Metabolism |
0.1 |
S |
|
P13796 |
L-plastin |
6.42 |
95.10 |
Function Not Assigned |
0.1 |
A, S |
|
P54108 |
Cysteine-rich secretory protein-3 precursor |
8.11 |
25.50 |
Immune Response |
0.1 |
|
|
O43707 |
Alpha-actinin 4 |
5.27 |
104.80 |
Cell Organization |
0.09 |
|
|
P06733 |
Alpha enolase |
5.71 |
13.20 |
Metabolism |
0.09 |
|
|
P11142 |
Heat shock cognate 71 kDa protein |
5.01 |
70.40 |
Metabolism |
0.09 |
S |
|
P18206 |
Vinculin |
6.44 |
331.60 |
Transport |
0.09 |
S |
|
P26038 |
Moesin |
6.09 |
67.60 |
Cell Organization |
0.09 |
|
|
P27482 |
Calmodulin-related protein NB-1 |
4.30 |
16.70 |
Immune Response |
0.09 |
|
|
P32926 |
Desmoglein-3 precursor |
4.76 |
101.70 |
Transport |
0.09 |
|
|
P67936 |
Tropomyosin alpha 4 chain |
4.67 |
28.40 |
Function Not Assigned |
0.09 |
S |
|
Q02487 |
Desmocollin-2 precursor |
4.80 |
84.70 |
Transport |
0.09 |
|
|
Q9UGL9 |
NICE-1 protein |
9.13 |
9.70 |
Function Not Assigned |
0.09 |
|
|
P00558 |
Phosphoglycerate kinase 1 |
8.30 |
44.50 |
Metabolism |
0.08 |
|
|
P01625 |
Ig kappa chain V-IV region Len |
7.92 |
12.63 |
Immune Response |
0.08 |
A, S |
|
P01871 |
Ig mu chain C region |
6.35 |
49.50 |
Immune Response |
0.08 |
A |
|
P16402 |
Histone H1.3 |
11.02 |
22.20 |
Cell Organization |
0.08 |
|
|
P63104 |
14-3-3 protein zeta/delta |
4.73 |
27.70 |
Metabolism |
0.08 |
A |
|
P02679 |
Fibrinogen gamma chain precursor |
5.24 |
48.50 |
Cell Proliferation |
0.07 |
A, S |
|
P08311 |
Cathepsin G precursor |
9.89 |
25.50 |
Metabolism |
0.07 |
|
|
P60174 |
Triosephosphate isomerase |
6.51 |
26.50 |
Metabolism |
0.07 |
|
|
P80723 |
Brain acid soluble protein 1 |
4.64 |
22.50 |
Function Not Assigned |
0.07 |
|
|
P01617 |
Ig kappa chain V-II region TEW |
5.69 |
12.30 |
Immune Response |
0.06 |
S |
|
P01620 |
Ig kappa chain V-III region SIE |
8.70 |
11.80 |
Immune Response |
0.06 |
A, S |
|
P05387 |
60S acidic ribosomal protein P2 |
4.26 |
11.50 |
Metabolism |
0.06 |
|
|
P11021 |
78 kDa glucose-regulated protein precursor |
4.82 |
11.60 |
Metabolism |
0.06 |
S |
|
P29373 |
Retinoic acid-binding protein II, cellular |
5.43 |
15.60 |
Metabolism |
0.06 |
|
|
O75223 |
Protein C7orf24 |
5.07 |
21.00 |
Function Not Assigned |
0.05 |
|
|
P07900 |
Heat shock protein HSP 90-alpha |
5.88 |
37.80 |
Transport |
0.05 |
|
|
P13987 |
CD59 glycoprotein precursor |
5.20 |
70.20 |
Signal Transduction |
0.05 |
A |
|
P31151 |
S100 calcium-binding protein A7 |
6.26 |
11.31 |
Cell Differentiation |
0.05 |
|
|
P31947 |
14-3-3 protein sigma |
4.68 |
27.80 |
Cell Proliferation |
0.05 |
S |
|
P37837 |
Transaldolase |
6.36 |
37.50 |
Metabolism |
0.05 |
|
|
P47929 |
Galectin-7 |
7.00 |
14.90 |
Transport |
0.05 |
S |
|
Q16610 |
Extracellular matrix protein 1 precursor |
6.19 |
58.80 |
Signal Transduction |
0.05 |
A, S |
|
Q99880 |
Histone H2B.c |
10.32 |
13.81 |
Cell Organization |
0.05 |
S |
|
O95171 |
Sciellin |
9.38 |
75.30 |
Cell Differentiation |
0.04 |
|
|
P01028 |
Complement C4 precursor |
6.66 |
192.70 |
Immune Response |
0.04 |
A, S |
|
P01042 |
Kininogen precursor |
6.34 |
71.90 |
Immune Response |
0.04 |
A, S |
|
P04004 |
Vitronectin precursor |
9.11 |
11.70 |
Immune Response |
0.04 |
A, S |
|
P07237 |
Protein disulfide-isomerase precursor |
6.11 |
9.90 |
Metabolism |
0.04 |
S |
|
P08603 |
Complement factor H precursor |
11.37 |
26.70 |
Immune Response |
0.04 |
A, S |
|
P14618 |
Pyruvate kinase, isozymes M1/M2 |
7.95 |
57.70 |
Metabolism |
0.04 |
|
|
P20670 |
Histone H2A.o |
10.90 |
13.95 |
Cell Organization |
0.04 |
S |
|
P20810 |
Calpastatin |
4.99 |
76.50 |
Enzyme Regulator |
0.04 |
|
|
P22735 |
Protein-glutamine gamma-glutamyltransferase K |
5.68 |
89.70 |
Metabolism |
0.04 |
|
|
Q06830 |
Peroxiredoxin 1 |
8.27 |
22.10 |
Cell Differentiation |
0.04 |
|
|
Q13835 |
Plakophilin 1 |
9.29 |
82.80 |
Signal Transduction |
0.04 |
|
|
P00747 |
Plasminogen precursor |
7.04 |
90.50 |
Metabolism |
0.03 |
A, S |
|
P05386 |
60S acidic ribosomal protein P1 |
9.19 |
83.80 |
Metabolism |
0.03 |
|
|
P08670 |
Vimentin |
6.14 |
136.90 |
Function Not Assigned |
0.03 |
|
|
P28799 |
Granulins precursor |
6.43 |
63.50 |
Cell Proliferation |
0.03 |
|
|
P30086 |
Phosphatidylethanolamine-binding protein |
7.43 |
20.90 |
Enzyme Regulator |
0.03 |
|
|
P35237 |
Placental thrombin inhibitor |
5.18 |
42.60 |
Enzyme Regulator |
0.03 |
|
|
P01591 |
Immunoglobulin J chain |
4.62 |
15.60 |
Immune Response |
0.02 |
S |
|
P02647 |
Apolipoprotein A-I precursor |
5.56 |
30.80 |
Metabolism |
0.02 |
A, S |
|
P02675 |
Fibrinogen beta chain precursor |
8.54 |
55.90 |
Cell Proliferation |
0.02 |
A, S |
|
P13639 |
Elongation factor 2 |
10.72 |
15.60 |
Metabolism |
0.02 |
|
|
P18669 |
Phosphoglycerate mutase 1 |
5.46 |
17.10 |
Metabolism |
0.02 |
A |
|
Q9UBX7 |
Kallikrein 11 precursor |
9.23 |
31.03 |
Metabolism |
0.02 |
|
|
Q9UKR3 |
Kallikrein 13 precursor |
8.79 |
28.90 |
Metabolism |
0.02 |